Skip to main content

Research Repository

Advanced Search

All Outputs (68)

Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) (2016)
Journal Article
Chalmers, J., Simpson, E., Apfelbacher, C., Thomas, K., von Kobyletzki, L., Schmitt, J., …Spuls, P. (2016). Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 175(1), 69-79. https://doi.org/10.1111/bjd.14773

This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmö, Sweden on 23–24 April 2015 (HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instrument... Read More about Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).

The epidemiology of childhood psoriasis: a scoping review (2016)
Journal Article
Burden-Teh, E., Thomas, K. S., Ratib, S., Grindlay, D. J., Adaji, E., & Murphy, R. (2016). The epidemiology of childhood psoriasis: a scoping review. British Journal of Dermatology, 174(6), 1242-1257. https://doi.org/10.1111/bjd.14507

Psoriasis is an inflammatory noncommunicable skin disease that affects both adults and children. At present, the epidemiology and natural history of psoriasis are not widely understood. This scoping review aimed to map the existing literature on the... Read More about The epidemiology of childhood psoriasis: a scoping review.

Validation of treatment escalation as a definition of atopic eczema flares (2015)
Journal Article
Thomas, K. S., Stuart, B., O’Leary, C., Schmitt, J., Paul, C., Williams, H., & Langan, S. (2015). Validation of treatment escalation as a definition of atopic eczema flares. PLoS ONE, 10(4), 1-13. https://doi.org/10.1371/journal.pone.0124770

Background Atopic eczema (AE) is a chronic disease with flares and remissions. Long-term control of AE flares has been identified as a core outcome domain for AE trials. However, it is unclear how flares should be defined and measured. Objective... Read More about Validation of treatment escalation as a definition of atopic eczema flares.

The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology (2015)
Journal Article
Schmitt, J., Apfelbacher, C., Spuls, P. I., Thomas, K. S., Simpson, E. L., Furue, M., …Williams, H. C. (2015). The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. Journal of Investigative Dermatology, 135(1), 24-30. https://doi.org/10.1038/jid.2014.320

Core outcome sets (COSs) are consensus-derived minimum sets of outcomes to be assessed in a specific situation. COSs are being increasingly developed to limit outcome-reporting bias, allow comparisons across trials, and strengthen clinical decision m... Read More about The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology.

The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials (2014)
Journal Article
Schmitt, J., Spuls, P. I., Thomas, K. S., Simpson, E., Furue, M., Deckert, S., …Williams, H. C. (2014). The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. Journal of Allergy and Clinical Immunology, 134(4), 800-807. https://doi.org/10.1016/j.jaci.2014.07.043

The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing evidence-based treatment. The global Harmonising Outcome Measures for Eczema (HOME) initiative has already defined clinical signs, symptoms, quality of life, and l... Read More about The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials.

Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention (2014)
Journal Article
Simpson, E. L., Chalmers, J. R., Hanifin, J. M., Thomas, K. S., Cork, M. J., Irwin McLean, W., …Williams, H. C. (2014). Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology, 134(4), 818-823. https://doi.org/10.1016/j.jaci.2014.08.005

Atopic dermatitis (atopic eczema) is a chronic inflammatory skin disease that has reached epidemic proportions in children worldwide and is increasing in prevalence. Because of the significant socioeconomic effect of atopic dermatitis and its effect... Read More about Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention.

Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials. (2014)
Journal Article
Mason, J. M., Thomas, K., Crook, A. M., Foster, K. A., Chalmers, J., Nunn, A. J., & Williams, H. C. (2014). Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials. PLoS ONE, 9(2), https://doi.org/10.1371/journal.pone.0082694

Background Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. We assessed the cost-effectiveness of prophylactic antibiotic treatment to prevent the recurrence of cellulitis using low dose... Read More about Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials..